Vaccines Incorporating Host or Viral Il-10 for Inducing Therapeutic Immune Responses

Tech ID: 29732 / UC Case 2018-646-0

Abstract

Researchers at the University of California, Davis have developed vaccines that incorporate host or viral Interleukin 10 (IL-10) to drive therapeutic immune responses.

Full Description

Many vaccine candidates induce robust immune responses, however, these immune responses are not preventative or therapeutic for the targeted diseases because they are qualitatively different from therapeutic responses. Vaccines may also provoke immune responses that are irrelevant or detrimental to the aim of protecting patients.Interleukin 10 (IL-10), also known as human cytokine synthesis inhibitory factor (CSIF), is a cytokine that affects immunoregulation and inflammation.

Researchers at the University of California, Davis have developed vaccines that incorporate host or viral IL-10 to drive therapeutic immune responses. These vaccines induce unique T cell responses that are potentially therapeutic against infectious diseases and cancers.

Applications

  • Vaccine with therapeutic immune responses

Features/Benefits

  • More reliably elicits effective immune responses
  • More reliably induces tolerance responses
  • High levels of unique T cell responses

Patent Status

Patent Pending

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Hartigan-O'Connor, Dennis

Other Information

Keywords

Interleukin 10, vaccine, IL-10, immune response, immunotherapy, human cytokine synthesis inhibitory factor, CSIF

Categorized As